For selected relapsed or treatment-resistant blood cancer cases, Beijing specialist centers may offer access to high-volume hematology teams and CAR-T pathways. Eligibility depends on diagnosis, prior treatment, disease status, and physician assessment.
Important — on cost comparisons: US CAR-T figures refer to drug-only wholesale acquisition costs (FDA manufacturer data: Kymriah/Yescarta). Beijing figures may include different treatment components. These numbers are not directly comparable unless inclusions are confirmed by the hospital. Individual costs depend on CAR-T product, disease status, hospitalisation length, complications, and physician assessment. Hospital confirmation is required before any cost commitment.
You do not need everything ready to submit an initial inquiry. But the more you can share, the more specific and useful our response will be.
Documents can be in any language — we handle translation as part of the coordination process.
This pathway may not be appropriate for patients requiring:
Important: Patients should not delay urgent local care while seeking overseas review. If your situation is time-sensitive, please continue with your local care team in parallel. We can assess feasibility alongside, not instead of, your current treatment.
These cases are reviewed individually. Some may not be appropriate for short-stay travel.
Beijing specialist hematology centers may treat blood cancer cases at high volume because complex cases are concentrated in leading referral institutions. For selected conditions such as relapsed or refractory leukemia and lymphoma, Beijing centers including GoBroad Boren Hospital have published clinical outcomes in peer-reviewed journals and presented at major international conferences including ASH and EHA. Higher case volume can matter because repetition builds familiarity with complex presentations; we prioritize centers where this experience is documented.
For patients who cannot access CAR-T or advanced hematology treatment in their home country due to cost, eligibility, or scheduling, Beijing specialist centers may offer an alternative pathway. International patients from multiple countries have been assessed and treated at GoBroad Boren Hospital. Whether a specific case is appropriate depends on diagnosis, disease status, and prior treatment history — which is why we review records before recommending any pathway.
We coordinate case review — we do not promise outcomes. A specialist assessment will clarify whether Beijing treatment is appropriate for your specific situation. Eligibility for any procedure depends on individual physician evaluation.
We don't lock you into one institution. Once you submit your case, we assess your diagnosis and match you with the specialist and hospital that appear most suitable for your specific condition.
One of China's most active CAR-T research centers — with clinical experience in relapsed and refractory leukemia, lymphoma, and myeloma, including international patient cases. Research published in Leukemia and Blood Cancer Journal; results presented at ASH and EHA. For patients exploring advanced hematology options, GoBroad Boren's documented case volume and published work may make it a credible starting point for specialist review.
For solid tumor cases, second opinions, and patients who need a multidisciplinary oncology review within an internationally accredited environment, PUIH is connected with Peking University Health Science Center as a clinical hospital and provides oncology services with full English-language support, international insurance support where available, and imaging capabilities subject to scheduling.
Whether that means a hematology specialist at GoBroad Boren, a multidisciplinary tumor board at Peking University International Hospital, or another center in our network — we assess your specific case and recommend the suitable fit. If you have a specific specialist or institution in mind, tell us and we will reach out on your behalf.
Share your pathology report, imaging, and current treatment history. We review and prepare a structured case summary for specialist review.
We organise your records and determine whether a hospital or physician-level review is appropriate. If specialist review is required, fees and timelines are confirmed before proceeding and which pathway makes most sense.
Video consultation with the matched specialist before you travel. You ask your questions, they review your records, and you get a clear picture of what treatment in Beijing would involve.
With a real assessment and an indicative hospital-confirmed cost estimate in hand, you make an informed decision. If you proceed, we coordinate everything from flights to discharge.
| Treatment | 🇺🇸 US Cost (Self-Pay) | 🇺🇸 US Wait | 🇨🇳 Beijing Cost | 🇨🇳 Beijing Timeline |
|---|---|---|---|---|
CAR-T Cell Therapy CD19, BCMA, CD22 targets | $373,000–$475,000 | 3–6 months | Case-dependent; hospital confirmation required | Timeline confirmed after specialist review |
Bone Marrow Transplant Allogeneic / autologous | $300,000–$900,000 | 2–4 months | $80,000–$150,000 | 3–6 weeks |
Chemotherapy (per cycle) Standard regimens | $10,000–$30,000/cycle | 2–4 weeks scheduling | $3,000–$8,000/cycle | 1–2 weeks |
Oncology Second Opinion Specialist review of records | $500–$2,000 + 6 week wait | 4–8 weeks | Included in assessment | 72 hours |
Cost references are indicative. US CAR-T figures are drug list prices only and are not directly comparable to any Beijing package unless inclusions are confirmed. Individual estimates require specialist case review and hospital confirmation.
Share your diagnosis and records. Within 72 hours after receiving your records, we will coordinate an initial review of whether a Beijing pathway may be appropriate — before you make any decision about travel.
Submit Cancer Case →CAR-T list prices are US manufacturer wholesale acquisition costs: Kymriah $475,000 (Novartis), Yescarta $373,000–$537,600 (Gilead/Kite), Breyanzi $410,000 (BMS) — drug cost only; total episode costs including hospitalization are higher (source: FDA; PMC/NCBI peer-reviewed literature). Beijing indicative ranges are for international patients and are case-dependent. BeijingMedAccess does not provide medical advice, diagnosis, or treatment. Eligibility for any treatment depends on individual diagnosis and physician assessment.
